Table 4. [Meta-Analyses of Cardiovascular Adverse Events...]. - Endotext

Study characteristics	Results
Haddad RM, 2007 (185)	30	808	834		No significant difference in odds ratio for any cardiovascular adverse event or MI.
Fernandez-Balsells MM, 2010 (147)	51	2,716		No significant difference for all-cause mortality, coronary bypass surgery or MI.
Xu L, 2013 (186)	27	2,994	T associated with increased risk cardiovascular-related event (OR 1.54, 95% CI=1.09-2.18)*.
Ruige JB, 2013 (187)	10 (>100 participants)	1,289	848		No significant difference in cardiovascular adverse events.
Corona G, 2014 (188)	75	3,016	2,448		No association of T supplementation with cardiovascular risk. For MACE OR=1.01 (95% CI 0.57-1.77).
Borst SE, 2015 (189)	35	3,703		No significant risk for cardiovascular-related adverse events.
Alexander GC, 2017 (190)	39, cut-off for T 10.4-16.7 nmol/L	3,230	2,221		No significant increase in risk of MI OR=0.87 (95% CI 0.39-1.93)*, stroke or mortality.
Elliott J, 2017 (191)	87, cut-off for T 12 nmol/L or cFT 225 pmol/L	1,462-2088	1,372-1,851		Improved QoL, libido, depression and erectile function. No increase in risk of adverse events.
Corona G, 2018 (192)	93	4,653	3,826		No clear effect of T on incidence of CVD events. For MACE OR=0.97 (95% CI 0.64-1.46).
Diem SJ, 2020 (193)	38	N/A	N/A		Small improvement in sexual function and quality of life. Pooled risk for adverse cardiovascular outcomes did not differ between groups (OR=1.22, 95% CI 0.66-2.23).*
Hudson J, 2022 (194)	35 RCTs: 17 included in IPD meta-analysis	1,750 (IPD)	1,681 (IPD)		No significant difference between groups. For cardiovascular or cerebrovascular events OR=1·07 (95% CI 0·81–1·42).

Study characteristics

Results

Study author and year

N of RCTs

N
active

N placebo

Adverse signal

No adverse signal

Haddad RM, 2007 (185)

808

834

No significant difference in odds ratio for any cardiovascular adverse event or MI.

Fernandez-Balsells MM, 2010 (147)

2,716

No significant difference for all-cause mortality, coronary bypass surgery or MI.

Xu L, 2013 (186)

2,994

T associated with increased risk cardiovascular-related event (OR 1.54, 95% CI=1.09-2.18)*.

Ruige JB, 2013 (187)

10 (>100 participants)

1,289

848

No significant difference in cardiovascular adverse events.

Corona G, 2014 (188)

3,016

2,448

No association of T supplementation with cardiovascular risk. For MACE OR=1.01 (95% CI 0.57-1.77).

Borst SE, 2015 (189)

3,703

No significant risk for cardiovascular-related adverse events.

Alexander GC, 2017 (190)

39, cut-off for T 10.4-16.7 nmol/L

3,230

2,221

No significant increase in risk of MI OR=0.87 (95% CI 0.39-1.93)*, stroke or mortality.

Elliott J, 2017 (191)

87, cut-off for T 12 nmol/L or cFT 225 pmol/L

1,462-2088

1,372-1,851

Improved QoL, libido, depression and erectile function. No increase in risk of adverse events.

Corona G, 2018 (192)

4,653

3,826

No clear effect of T on incidence of CVD events. For MACE OR=0.97 (95% CI 0.64-1.46).

Diem SJ, 2020 (193)

N/A

Small improvement in sexual function and quality of life. Pooled risk for adverse cardiovascular outcomes did not differ between groups (OR=1.22, 95% CI 0.66-2.23).*

Hudson J, 2022 (194)

35 RCTs: 17 included in IPD meta-analysis

1,750 (IPD)

1,681 (IPD)

No significant difference between groups. For cardiovascular or cerebrovascular events OR=1·07 (95% CI 0·81–1·42).

From: Androgens and Cardiovascular Disease in Men

Endotext [Internet].

Feingold KR, Anawalt B, Blackman MR, et al., editors.

South Dartmouth (MA): MDText.com, Inc.; 2000-.

This electronic version has been made freely available under a Creative Commons (CC-BY-NC-ND) license. A copy of the license can be viewed at http://creativecommons.org/licenses/by-nc-nd/2.0/.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.